{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:16:33Z","timestamp":1787026593380,"version":"build-2736575974"},"reference-count":32,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T00:00:00Z","timestamp":1762128000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To evaluate the diagnostic and staging value of 18F-FDG PET\/CT in solitary malignant tumors of the spleen (SMTS).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed clinical data, 18F-FDG PET\/CT and contrast-enhanced CT findings from 25 pathologically confirmed SMTS cases. The PET\/CT characteristics including lesion distribution, accompanying signs, maximum standardized uptake value (SUVmax), and pathological types were analyzed, with comparison of diagnostic and staging efficacy between PET\/CT and contrast-enhanced CT.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      All 25 SMTS cases showed FDG uptake on PET\/CT: mild uptake in 2 cases (SUVmax 2.4 and 2.3 respectively), moderate uptake in 8 cases (SUVmax 6.4\u202f\u00b1\u202f3.5), and intense uptake in 15 cases (SUVmax 15.8\u202f\u00b1\u202f4.2). The metabolic patterns included homogeneous uptake (13 cases), rim-like uptake (10 cases), and diffuse uptake (2 cases). CT morphology revealed round\/oval lesions in 16 cases (64%, longest diameter 11.8\u202f\u00b1\u202f4.5\u202fcm), irregular lesions in 7 cases (28%, 17.6\u202f\u00b1\u202f5.7\u202fcm), and diffuse splenomegaly in 2 cases (8%, 18.4\u202f\u00b1\u202f2.7\u202fcm). Lesions demonstrated well-defined margins (4 cases) or ill-defined margins (21 cases), with central necrosis\/cystic degeneration\/hemorrhage (13 cases) or solid appearance (12 cases). Contrast-enhanced CT showed mild (7 cases, 28%), moderate (8 cases, 32%), and marked enhancement (9 cases, 36%). Pathological types included lymphoma (14 cases, mostly showing homogeneous hypermetabolism except 2 MALT lymphomas with hypometabolism), angiosarcoma (7 cases, all demonstrating rim-like uptake with with photopenia in the necrotic centers), other sarcomas (3 cases including 2 EBV-positive inflammatory follicular dendritic cell sarcomas with well-defined hypermetabolic lesions and 1 unclassified sarcoma with heterogeneous uptake), and solitary metastasis (1 case showing nodular hypermetabolism). PET\/CT demonstrated significantly higher diagnostic sensitivity (84% vs. 68%,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.012) and superior staging capability (28% vs. 12%,\n                      <jats:italic>p<\/jats:italic>\n                      \u202f=\u202f0.027) compared to CT, the diagnostic sensitivity of PET\/CT combined with enhanced CT was 96%.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>18F-FDG PET\/CT provides significant diagnostic and staging value for SMTS, with SUVmax and metabolic patterns improving diagnostic accuracy. The combination of PET\/CT and pathological biopsy is recommended for optimal evaluation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2025.1647670","type":"journal-article","created":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:21:35Z","timestamp":1762147295000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Utility of 18F-FDG PET\/CT for diagnosing and staging solitary malignant tumors of the spleen"],"prefix":"10.3389","volume":"12","author":[{"given":"Mingyan","family":"Shao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sisi","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanling","family":"Qi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,3]]},"reference":[{"key":"ref1","first-page":"83","article-title":"WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview","volume":"102","author":"Sabattini","year":"2010","journal-title":"Pathologica"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"100466","DOI":"10.1016\/j.modpat.2024.100466","article-title":"Fifth edition of the World Health Organization classification of tumors of the hematopoietic and lymphoid tissues: acute lymphoblastic leukemias, mixed-phenotype acute leukemias, myeloid\/lymphoid neoplasms with eosinophilia, dendritic\/histiocytic neoplasms, and genetic tumor syndromes","volume":"37","author":"Choi","year":"2024","journal-title":"Mod Pathol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1007\/s00104-023-01978-8","article-title":"Chirurgie bei prim\u00e4ren Milztumoren und Metastasen der Milz","volume":"94","author":"Huettl","year":"2023","journal-title":"Chirurgie"},{"key":"ref4","first-page":"52","article-title":"Solid splenic masses: evaluation with 18F-FDG PET\/CT","volume":"46","author":"Metser","year":"2005","journal-title":"J Nucl Med"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1007\/s00330-024-10961-8","article-title":"Diagnostic ability of [18F]FDG PET\/CT for distinguishing benign from malignant spleen lesions","volume":"35","author":"Lee","year":"2025","journal-title":"Eur Radiol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"85","DOI":"10.59566\/IJBS.2009.5085","article-title":"Primary tumors of the spleen","volume":"5","author":"Fotiadis","year":"2009","journal-title":"Int J Biomed Sci"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/j.immuni.2013.10.010","article-title":"The spleen in local and systemic regulation of immunity","volume":"39","author":"Bronte","year":"2013","journal-title":"Immunity"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1080\/01926230600867743","article-title":"Normal structure, function, and histology of the spleen","volume":"34","author":"Cesta","year":"2006","journal-title":"Toxicol Pathol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"2643","DOI":"10.4049\/jimmunol.1002983","article-title":"B lymphocytes differentially influence acute and chronic allograft rejection in mice","volume":"186","author":"DiLillo","year":"2011","journal-title":"J Immunol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1126\/science.1175202","article-title":"Identification of splenic reservoir monocytes and their deployment to inflammatory sites","volume":"325","author":"Swirski","year":"2009","journal-title":"Science"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1038\/s41586-018-0735-5","article-title":"Efferocytosis induces a novel SLC program to promote glucose uptake and lactate release","volume":"563","author":"Morioka","year":"2018","journal-title":"Nature"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/s41577-019-0127-6","article-title":"Macrophages as regulators of tumour immunity and immunotherapy","volume":"19","author":"DeNardo","year":"2019","journal-title":"Nat Rev Immunol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"e36688","DOI":"10.7554\/eLife.36688","article-title":"Chimeric antigen receptors that trigger phagocytosis","volume":"7","author":"Meghan","year":"2018","journal-title":"eLife"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1510","DOI":"10.1126\/science.1118948","article-title":"Divergent immunoglobulin g subclass activity through selective fc receptor binding","volume":"310","author":"Nimmerjahn","year":"2005","journal-title":"Science"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1016\/j.surg.2021.09.024","article-title":"Solid tumor of the spleen: a challenging diagnosis","volume":"171","author":"Carboni","year":"2022","journal-title":"Surgery"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1102\/1470-7330.2010.0026","article-title":"Primary and secondary neoplasms of the spleen","volume":"10","author":"Kaza","year":"2010","journal-title":"Cancer Imaging"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"3560","DOI":"10.1007\/s00259-021-05322-2","article-title":"Total metabolic tumor volume and spleen metabolism on baseline [18F]-FDG PET\/CT as independent prognostic biomarkers of recurrence in resected breast cancer","volume":"48","author":"Seban","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1097\/RLU.0000000000000523","article-title":"Use of 18F-FDG PET\/CT imaging for evaluation of patients with primary splenic lymphoma","volume":"39","author":"Karunanithi","year":"2014","journal-title":"Clin Nucl Med"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.1007\/s00261-018-1542-z","article-title":"18F-FDG PET\/CT in splenic marginal zone lymphoma","volume":"43","author":"Albano","year":"2018","journal-title":"Abdom Radiol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"e20","DOI":"10.1097\/RLU.0000000000002717","article-title":"FDG-PET\/CT demonstrates splenic Angiosarcoma bone marrow metastasis","volume":"45","author":"Takahashi","year":"2020","journal-title":"Clin Nucl Med"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1097\/RLU.0000000000001805","article-title":"FDG PET\/CT in primary splenic angiosarcoma with diffuse involvement of the spleen","volume":"42","author":"Zhao","year":"2017","journal-title":"Clin Nucl Med"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1366560","DOI":"10.3389\/fonc.2024.1366560","article-title":"Application value of 18F-FDG PET\/CT in primary spleen angiosarcoma with liver metastasis: a case report and literature review","volume":"14","author":"Shao","year":"2024","journal-title":"Front Oncol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"476","DOI":"10.1097\/PAS.0000000000002011","article-title":"Challenges in the diagnosis of Epstein-Barr virus-positive inflammatory follicular dendritic cell sarcoma: extremely wide morphologic spectrum and immunophenotype","volume":"47","author":"Li","year":"2023","journal-title":"Am J Surg Pathol"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1186\/s12885-023-11334-y","article-title":"Clinical application of real-time PET\/CT guided targeted retroperitoneal masses biopsy in diagnosing malignant tumors","volume":"23","author":"Li","year":"2023","journal-title":"BMC Cancer"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1148\/radiol.2213010445","article-title":"PET-CT-guided percutaneous puncture of an infected cyst in autosomal dominant polycystic kidney disease: case report","volume":"221","author":"Kaim","year":"2001","journal-title":"Radiology"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1186\/s40644-024-00804-6","article-title":"[18F]FDG PET\/CT performs better than CT in determining the bone biopsy site: randomized controlled clinical trial","volume":"24","author":"Chang","year":"2024","journal-title":"Cancer Imaging"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1097\/RLU.0000000000002020","article-title":"FDG PET\/CT findings in a localized reactive lymphoid hyperplasia of the spleen","volume":"43","author":"Ito","year":"2018","journal-title":"Clin Nucl Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1097\/MNM.0b013e32832fa254","article-title":"Clinical significance of diffusely increased splenic uptake on FDG-PET","volume":"30","author":"Liu","year":"2009","journal-title":"Nucl Med Commun"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0000000000005947","article-title":"False-positive uptake in splenic hamartoma on 68Ga-DOTATATE PET\/CT","author":"Wu","year":"2025","journal-title":"Clin Nucl Med"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1097\/RLU.0000000000004626","article-title":"False-Positive Uptake in Splenic Hemangioma on 68 Ga-DOTATATE PET\/CT","volume":"48","author":"Zhu","year":"2023","journal-title":"Clin Nucl Med"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"130","DOI":"10.3390\/curroncol29010011","article-title":"Introduction to a special issue on low-grade B cell lymphoma in the spleen","volume":"29","author":"Nava","year":"2021","journal-title":"Curr Oncol"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"779","DOI":"10.1007\/s00259-013-2343-9","article-title":"When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET?","volume":"40","author":"Cheng","year":"2013","journal-title":"Eur J Nucl Med Mol Imaging"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1647670\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,3]],"date-time":"2025-11-03T05:21:36Z","timestamp":1762147296000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1647670\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,3]]},"references-count":32,"alternative-id":["10.3389\/fmed.2025.1647670"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1647670","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,3]]},"article-number":"1647670"}}